

Your CIMZIA treatment journey starts here



Indications

CIMZIA is approved for the treatment of adults with:

- moderate to severe rheumatoid arthritis (RA)
- active psoriatic arthritis (PsA)
- active ankylosing spondylitis (AS)
- moderate to severe Crohn's disease (CD) who have not been helped enough by usual treatments
- moderate-to-severe plaque psoriasis (PsO) who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills)
- active non-radiographic axial spondyloarthritis (nr-axSpA) with measures of inflammation

Important Safety Information

CIMZIA can lower the ability of your immune system to fight infections. Some people who received CIMZIA have developed serious infections, including tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some of these serious infections have caused hospitalization and death.

Contents

- **4** Welcome to CIMZIA[®] (certolizumab pegol)
- **5** What Is CIMZIA?
- 6 What Can You Expect When Receiving CIMZIA at Your Doctor's Office?
 - **7** Receiving your injections at your doctor's office
 - 8 A step-by-step guide to your treatment visit
- **10** Important Safety Information
- 12 Support With CIMplicity®
 - **13** Savings options
 - 14 Nurse Navigator support

Learn more about what to expect at an injection appointment and how the CIMplicity program can offer support for your treatment journey.



Welcome to CIMZIA®

For over 14 years, doctors have chosen CIMZIA (certolizumab pegol) to help their adult patients with various chronic inflammatory conditions.

We understand this journey may oftentimes not be easy. We'll go through it, together. Rest assured, we are ready to support you in order to help you move forward with confidence.

For more information about CIMZIA and the free support resources available to you, visit CIMZIA.com.



What Is CIMZIA®?

As an injectable treatment, CIMZIA (certolizumab pegol) treats your condition where it starts, inside the body. CIMZIA is a biologic, meaning it's made from living cells. More specifically, it's an anti-TNF (anti-tumor necrosis factor). TNF is a natural substance in your body that signals immune cells to fight infections and disease. But too much TNF in your body can cause immune cells to attack healthy tissue, leading to the symptoms you're experiencing.

By blocking the extra signals to immune cells, CIMZIA helps reduce the inflammation that often leads to symptoms. And CIMZIA is designed to slowly exit the body, meaning you can take it less frequently and still manage your symptoms.

Were you recently diagnosed? **To learn more about your condition's symptoms**, **visit CIMZIA.com**.

> Your Nurse Navigator* can assist you with further questions you have about CIMZIA, including goal-setting and financial support services. **See page 14 to learn more.**

*Nurse Navigators do not provide medical advice and will refer you to your healthcare professional for any treatment-related questions.

Please read additional Important Safety Information on pages 10-11 and accompanying full Prescribing Information, including Medication Guide, and visit CIMZIA.com.

Important Safety Information

Patients 65 years of age or older, patients with other long-term medical conditions, or patients taking certain other drugs that affect the immune system, such as corticosteroids or methotrexate, may be at a greater risk of infection.

What can you expect when receiving CIMZIA® at your doctor's office?

CIMZIA is given as an injection under the skin during a standard office visit. This is not an intravenous (IV) infusion, it is a formulation that is mixed, prepared, and injected in the thigh or the abdomen by a healthcare provider.

There are two dosing phases that patients will follow on CIMZIA—dosing for the first month and ongoing dosing. **You and your doctor will decide which ongoing (maintenance) dose is right for you.**

MONTH 1 DOSING
ALL INDICATIONS
400 mg (2 injections x 200 mg/mL) WEEKS 0, 2, 4
ONGOING DOSING
400 mg (2 injections x 200 mg/mL) EVERY 4 WEEKS
RA PSA AS CRSPA
400 mg 2 injections x 200 mg/mL) EVERY 4 WEEKS CR (1 injection x 200 mg/mL) EVERY 2 WEEKS
Pso
400 mg (2 injections x 200 mg/mL)
EVERY 2 WEEKS
ALTERNATE DOSING FOR PSO For some patients (with body weight <90 kg), a dose of 400 mg (given as 2 subcutaneous injections of 200 mg each) initially and at weeks 2 and 4, followed by 200 mg

every other week, may be considered.

Receiving your injections at your doctor's office

Once you've been prescribed in-office injections, you'll work with your doctor's office to schedule your treatment sessions.



TREATMENT SHIPPING

Your medicine will be sent to the doctor's office or medical facility where you will receive your treatment. Your doctor's office orders the medication and may bill your insurance for the cost.



TREATMENT SCHEDULING

Your doctor's office will schedule a time for you to receive the first dose of medication.

TREATMENT PREP

When you arrive, the doctor's office staff will likely perform some basic checks (such as temperature or blood pressure) to ensure you can receive your treatment.

Important Safety Information

Allergic reactions may occur. Signs of an allergic reaction include a skin rash; swelling or itching of the face, tongue, lips or throat; or trouble breathing. The plastic needle shield inside the removable cap of the prefilled syringe contains natural rubber and may cause an allergic reaction if you are sensitive to latex.



A step-by-step guide to your treatment visit

The breakdown below shows you what may happen during your CIMZIA® (certolizumab pegol) In-Office Injection appointment. These steps are examples and may vary within the individual practice.



CHECK IN

The office staff may consider reverifying your benefits before your appointment, and they may collect your co-pay upon arrival (if applicable).

Step 3



PREPARATION OF CIMZIA®

The office will get your dose of CIMZIA ready for your treatment. This may take as long as 30 minutes, as the CIMZIA will need to reach room temperature before injection.



GET YOUR CIMZIA

You may be escorted back to a private area, exam room, or infusion suite to receive your injection under your skin in the abdomen or thigh. Ask your doctor any questions you may have before you leave, which should be shortly after your injection.



RECEIVE PRETREATMENT CHECK

The nurse may assess your readiness for injection (such as confirming you have no signs of infection, including elevated temperature).

Step 5

CHECK OUT

You're almost done!

Just schedule or confirm your future injection appointments, and you will be on your way.

Important Safety Information

New or worsening of nervous system problems may occur, such as multiple sclerosis, Guillain-Barre syndrome, seizures, or inflammation of the nerves of the eyes. Symptoms include dizziness, numbness or tingling, problems with your vision, and weakness in your arms or legs.

IMPORTANT SAFETY INFORMATION YOU SHOULD KNOW ABOUT CIMZIA[®] (certolizumab pegol)

What is the most important information I should know about CIMZIA?

CIMZIA may cause serious side effects. includina:

- CIMZIA is a prescription medicine called a Tumor Necrosis Factor (TNF) blocker that can lower the ability of your immune system to fight infections. Some people who received CIMZIA have developed serious infections, including tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some of these serious infections have caused hospitalization and death.
- Your healthcare provider should test you for TB before starting CIMZIA.
- Your healthcare provider should monitor you closely for signs and symptoms of TB during treatment with CIMZIA.

Before starting CIMZIA, tell your healthcare provider if you:

- think you have an infection or have symptoms of an infection such as:
 - o fever, sweat, or chills
 - o cough
 - o blood in phlegm o warm, red, or painful skin or
 - sores on your body
 - o burning when you urinate or urinate more often than normal

 - o muscle aches o shortness of breath
 - o weight loss

 - o diarrhea or stomach pain o feeling very tired
- are being treated for an infection
- aet a lot of infections or have infections that keep coming back
- have diabetes, HIV-1 or a weak immune system. People with these conditions have a higher chance for infections.
- have tuberculosis (TB), or have been in close contact with someone with TR
- were born in, live, have lived, or traveled to certain countries where there is more risk for getting TB. Ask your healthcare provider if you are not sure.
- live, have lived, or traveled to certain parts of the country (such as the Ohio and Mississippi River valleys and the Southwest) where there is an increased risk for aetting certain kinds of fungal infections (histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis). These infections may develop or become more severe if you receive CIMZIA. Ask your healthcare provider if you do not know if you have lived in an area where these infections are common.
- have or have had hepatitis B
- use the medicine Kineret[®] (anakinra), Orencia® (abatacept), Rituxan® (rituximab), or Tysabri® (natalizumab)

Stop using CIMZIA, and tell your healthcare provider right away if you have any of the symptoms of an

infection listed above. • Cancer

- For people who receive TNF blockers,
- including CIMZIA, the chances of getting certain types of cancers may increase
- Some children, teenagers, and young adults who received TNF blockers. including CIMZIA, have developed lymphoma and other certain types of rare cancers, some of which have caused death. These cancers are not usually seen in this age group. CIMZIA is not for use in children.
- · People with inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, or ankylosina spondylitis, especially those with very active disease, may be more likely to get lymphoma.
- · Some people who receive TNF blockers, including CIMZIA, have developed a rare type of cancer which may cause death, called hepatosplenic T-cell lymphoma. Most of these people were male teenagers and young adult males with Crohn's disease or ulcerative colitis. Also, most of these people had been treated with both a TNF blocker and another medicine called IMURAN® (azathioprine) or PURINETHOL® (6-mercaptopurine, 6-MP).
- Some people who receive CIMZIA have developed certain types of skin cancer. Tell your healthcare provider if you develop any changes in the appearance of your skin, including growths on your skin, during or after treatment with CIMZIA. You should see your healthcare provider periodically during treatment for skin examinations, especially if you have a history of skin cancer.

What is CIMZIA?

CIMZIA is a prescription medicine called a Tumor Necrosis Factor (TNF) blocker used in adults to:

- Lessen the signs and symptoms of moderately to severely active Crohn's disease (CD) in adults who have not been helped enough by usual treatments
- Treat moderately to severely active rheumatoid arthritis (RA)
- Treat active psoriatic arthritis (PsA)
- Treat active ankylosing spondylitis (AS)
- Treat active non-radiographic axial spondyloarthritis (nr-axSpA) with measures of inflammation
- Treat moderate to severe plaque psoriasis (PsO) in adults who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills)

It is not known if CIMZIA is safe and effective in children.

Before receiving CIMZIA, tell your healthcare provider about all of your medical conditions, including if you:

- have an infection
- have or have had lymphoma or any other type of cancer
- have or had congestive heart failure
- have or have had seizures, any numbness or tingling, or a disease that affects your nervous system such as multiple sclerosis or Guillain-Barre syndrome.
- are scheduled to receive a vaccine. Do not receive a live vaccine while receiving CIMZIA.
- are allergic to certolizumab pegol or any of the ingredients in CIMZIA. See the Medication Guide for a complete list of the ingredients in CIMZIA.
- are pregnant or plan to become pregnant. You and your doctor should decide if you should continue to take CIMZIA while you are pregnant. It is not known if ĆIMZIA will harm your unborn baby. Pregnancy Registry: If you become pregnant during treatment with CIMZIA, talk to your healthcare provider about registering in the pregnancy exposure registry for CIMZIA. You can enroll in this registry by calling 1-877-311-8972. The purpose of this registry is to collect information about the safety of CIMZIA during pregnancy.
- are breastfeeding or plan to breastfeed. Talk to your healthcare provider about the best way to feed your baby during treatment with CIMZIA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.

How will I receive CIMZIA?

CIMZIA comes as a lyophilized powder or a solution in a prefilled syringe for injection. If your healthcare provider prescribes the CIMZIA powder, CIMZIA should be injected by a healthcare provider. If your healthcare provider prescribes the prefilled syringe, you will be trained on how to inject CIMZIA. See the booklet called "Instructions for Use" packaged in your CIMZIA prefilled syringe kit on how to inject CIMZIA the right way. Do not give yourself an injection of CIMZIA unless you have been shown by your healthcare provider, or they can train someone you know to help you with your injection. CIMZIA is given by an injection under the skin. Your healthcare provider will tell you how much and how often to inject CIMZIA. Do not use more CIMZIA or inject more often than prescribed.

What are the possible side effects of CIMZIA? CIMZIA can cause serious side effects, including:

- See "What is the most important information I should know about CIMZIA?"
- Heart failure including new heart failure or worsening of heart failure

you already have. Symptoms include shortness of breath, swelling of your ankles or feet, or sudden weight gain.

- Allergic reactions. Signs of an allergic reaction include a skin rash: swelling or itching of the face, tongue, lips, or throat; or trouble breathing. The plastic needle shield inside the removable cap of the prefilled syringe contains natural rubber and may cause an allergic reaction if you are sensitive to latex.
- Hepatitis B virus reactivation in people who carry the virus in their blood. In some cases, people who received CIMZIA have died because of the hepatitis B virus being reactivated. Your healthcare provider should monitor you carefully before and during treatment with CIMZIA to see if you carry the hepatitis B virus in your blood. Tell your healthcare provider if you have any of the following symptoms:
 - o feel unwell
 - o tiredness (fatigue)
 - o pain on the right side of your stomach (abdomen) o skin or eyes look yellow o poor appetite or vomiting
- New or worsening nervous system problems, such as multiple sclerosis (MS), Guillain-Barre syndrome, seizures, or inflammation of the nerves of the eyes. Symptoms may include:
 - o dizziness
 - o problems with your vision
 - o numbness or tingling
 - o weakness in your arms or legs
- Blood problems. Your body may not make enough of the blood cells that help fight infections or help stop bleeding. Symptoms include a fever that does not go away, bruising or bleeding very easily, or looking very pale. Tell your healthcare provider right away if you have any bruising, bleeding or a fever that does not go away.
- Immune reactions including a lupuslike syndrome. Symptoms include shortness of breath, joint pain, or a rash on your cheeks or arms that worsens with sun exposure.

Call your healthcare provider right away if you have any serious side effects listed above.

The most common side effects of **CIMZIA include** upper respiratory infections (flu, cold), rash, and urinary tract infections (bladder infections).

These are not all of the possible side effects of CIMZIA. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see the Medication Guide for CIMZIA and discuss it with your healthcare provider.

Support with

SUPPORTING YOU EVERY STEP OF THE WAY

Enrolling in the CIMplicity[®] program is a simple way to help ensure a great start and a future full of support with your CIMZIA[®] treatment, including a dedicated **Nurse Navigator***.

From helping you achieve your treatment goals to making sure you pay as little as possible, your Nurse Navigator is ready to help find answers and get you started on our CIMplicity services, including:

 \$0 CIMplicity Savings Program: You may be eligible to receive treatment at no cost to you.⁺ Your Nurse Navigator can help determine if you qualify.

SIGN UP FOR CIMPLICITY IN 3 EASY STEPS

Scan QR code with your phone or visit CIMZIA.com/join.

2

Complete registration form.

Your CIMplicity Nurse Navigator will contact you by phone to welcome you to the program. Expect a call from 1-844-822-6877.

The CIMplicity program is provided as a service of UCB and is intended to support the appropriate use of CIMZIA. The CIMplicity program may be amended or canceled at any time without notice. Some program and eligibility restrictions may apply.

*Nurse Navigators do not provide medical advice and will refer you to your healthcare professional for any treatment-related questions.

*Eligibility: Available to individuals with commercial prescription insurance coverage for CIMZIA. Not valid for prescriptions that are reimbursed, in whole or in part, under Medicare (including Medicare Part D), Medicaid, similar federal- or state-funded programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), or where otherwise prohibited by law. Product dispensed pursuant to program rules and federal and state laws. Claims should not be submitted to any public payor (ie, Medicare, Medicaid, Medigap, TRICARE, VA, and DoD) for reimbursement. The maximum annual benefit amount is \$15,000 per calendar year. The parties reserve the right to amend or end this program at any time without notice.



I'm thrilled to be enrolled with you! 99

- Actual CIMZIA® patient



Important Safety Information

Heart failure, including new heart failure or worsening of heart failure, has been reported in people taking CIMZIA. Symptoms include shortness of breath, swelling of your ankles or feet, or sudden weight gain.

With the CIMplicity[®] Savings Program^{*}, you may be eligible for **\$0 copay**

WE KNOW HOW IMPORTANT IT IS FOR YOUR TREATMENT TO START QUICKLY ONCE PRESCRIBED

Cost shouldn't get in the way of your treatment. With the CIMplicity Savings Program, eligible, commercially insured patients may pay \$0 per dose for CIMZIA®:*



A member of your doctor's staff can enroll you in the program. The staff will also submit claims on your behalf.



You can also enroll in CIMplicity at CIMZIA.com/join.

If you do not have insurance, other financial assistance may be available. Call ucbCARES[®] at **1-844-599-CARE** (2273) for more information.

*Savings Program Eligibility: Available to individuals with commercial prescription insurance coverage for CIMZIA. Not valid for prescriptions that are reimbursed, in whole or in part, under Medicare (including Medicare Part D), Medicaid, similar federal- or state-funded programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), or where otherwise prohibited by law. Product dispensed pursuant to program rules and federal and state laws. Claims should not be submitted to any public payor (ie, Medicare, Medicaid, Medigap, TRICARE, VA, and DoD) for reimbursement. The maximum annual benefit amount is \$15,000 per calendar year. The parties reserve the right to amend or end this program at any time without notice.

Important Safety Information

Some people who receive CIMZIA have developed certain types of skin cancer. Tell your healthcare provider if you develop any changes in the appearance of your skin, including growths on your skin, during or after treatment with CIMZIA. You should see your healthcare provider periodically during treatment for skin examinations, especially if you have a history of skin cancer.

CIMplicity® Program Benefits

ONGOING NURSE SUPPORT

Your CIMplicity **Nurse Navigator**^{*} is your dedicated, compassionate point of contact for discussing your CIMZIA[®] journey and any additional financial questions.



From answering questions about your CIMZIA experience to providing you resources related to your treatment, your Nurse Navigator is ready so you can manage your condition with confidence.



You can enroll in CIMplicity, and enjoy benefits like Nurse Navigator support, at CIMZIA.com/join or by calling **1-844-UCB-NURSE** (1-844-822-6877).

CIMplicity Nurse Navigators[†] are a group of dedicated medical professionals committed to your success.

Spanish-language support is also available at 1-877-294-0280.



[†]Nurse Navigators do not provide medical advice and will refer you to your healthcare professional for any treatment-related questions.





You've taken an important first step.

Now, let's move forward together.

Enroll in CIMplicity® to gain access to services, tools, and resources that can support you throughout your treatment journey.

SIGN UP FOR CIMPLICITY IN 3 easy steps

1

Scan QR code with your phone or visit CIMZIA.com/join.

Complete registration form.



Your CIMplicity Nurse Navigator will contact you by phone to welcome you to the program. Expect a call from 1-844-822-6877.

Please read Important Safety Information on pages 10-11 and accompanying full Prescribing Information, including Medication Guide, and visit CIMZIA.com.



CIMZIA*, CIMplicity*, cimplicity*, and ucbCARES* are registered trademarks, and CIMplicity* Covered* is a trademark, of the UCB Group of Companies. All other trademarks are the property of their respective holders. ©2022 UCB, Inc., Smyrna, GA 30080. All rights reserved. US-P-CZ-AS-2200055